We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Catalent Inc | NYSE:CTLT | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.16 | 0.28% | 56.50 | 56.63 | 56.1786 | 56.20 | 1,712,987 | 01:00:00 |
From May 2019 to May 2024
By Colin Kellaher
Contract drug maker Catalent Inc. (CTLT) has agreed to buy Bristol-Myers Squibb Co.'s (BMY) oral solid, biologics and sterile product manufacturing and packaging plant in Anagni, Italy, for an undisclosed amount, the companies said Wednesday.
Catalent will continue to make Bristol-Myers' current product portfolio at the site, along with products for other customers, the companies said, adding that they expect to complete the transaction by the end of the year.
The manufacturing plant, with about 63,300 feet of floor space, sits on an 84-acre site roughly 60 miles southeast of Rome.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 19, 2019 09:23 ET (13:23 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Catalent Chart |
1 Month Catalent Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
